Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
19951.0k citationsLloyd Paul Aiello, Eric A. Pierce et al.profile →
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
Countries citing papers authored by Eric A. Pierce
Since
Specialization
Citations
This map shows the geographic impact of Eric A. Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric A. Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric A. Pierce more than expected).
This network shows the impact of papers produced by Eric A. Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric A. Pierce. The network helps show where Eric A. Pierce may publish in the future.
Co-authorship network of co-authors of Eric A. Pierce
This figure shows the co-authorship network connecting the top 25 collaborators of Eric A. Pierce.
A scholar is included among the top collaborators of Eric A. Pierce based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Eric A. Pierce. Eric A. Pierce is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Huckfeldt, Rachel M., Tomás S. Alemán, Xiaohong Wen, et al.. (2019). Subfoveal gene augmentation therapy for choroideremia: One-year results from a Phase I/II trial of AAV2-hCHM. Investigative Ophthalmology & Visual Science. 60(9). 6401–6401.1 indexed citations
7.
Alemán, Tomás S., Rachel M. Huckfeldt, Leona Serrano, et al.. (2019). AAV2-hCHM Subretinal Delivery to the Macula in Choroideremia: 2 year Results of an Ongoing Phase I/II Gene Therapy Trial. Investigative Ophthalmology & Visual Science. 60(9). 5173–5173.5 indexed citations
8.
Wassmer, Sarah, et al.. (2017). Evaluation of in silico reconstructed ancestral adeno-associated virus for gene augmentation therapy in a mouse model of LCA. Investigative Ophthalmology & Visual Science. 58(8). 4086–4086.1 indexed citations
9.
Pierce, Eric A., et al.. (2017). The Effect Of Vitamin A On Progression Of Retinitis Pigmentosa Is Not Determined By The Underlying Genetic Cause Of Disease. Investigative Ophthalmology & Visual Science. 58(8). 2011–2011.2 indexed citations
10.
Pan, Jianbo, Sheng Liu, Michael H. Farkas, et al.. (2016). Serum molecular signature for proliferative diabetic retinopathy in Saudi patients with type 2 diabetes.. PubMed. 22. 636–45.10 indexed citations
11.
Farkas, Michael H., Elizabeth D. Au, Maria E Sousa, & Eric A. Pierce. (2014). Transcriptome analyses reveal minimal aberrant splicing in mouse models of RNA splicing factor retinitis pigmentosa. Investigative Ophthalmology & Visual Science. 55(13). 4993–4993.1 indexed citations
12.
Morgan, Jessica I. W., Grace Han, Albert M. Maguire, et al.. (2013). Adaptive Optics Scanning Laser Ophthalmoscopy and High Resolution Imaging in Autosomal Dominant Retinitis Pigmentosa Caused by a Novel PRPF31 Nonsense Mutation. Investigative Ophthalmology & Visual Science. 54(15). 3445–3445.1 indexed citations
13.
Bowne, Sara J., Lori S. Sullivan, Jennifer D. Churchill, et al.. (2012). Genome-Wide Linkage Analysis For Gene Discovery In Autosomal Dominant Retinitis Pigmentosa. Investigative Ophthalmology & Visual Science. 53(14). 4528–4528.1 indexed citations
Farkas, Michael H., Kinga M. Bujakowska, John J. Graziotto, et al.. (2010). Characterization of Aberrant Splicing by Comparative Exon Microarray-Based Analysis in Mice With Targeted Mutations in Prpf3, Prpf8, and Prpf31. Investigative Ophthalmology & Visual Science. 51(13). 3667–3667.1 indexed citations
16.
Graziotto, John J., C.F. Inglehearn, & Eric A. Pierce. (2007). Characterization of Compound Knockin Prpf3/Prpf8 Mice. Investigative Ophthalmology & Visual Science. 48(13). 3002–3002.1 indexed citations
17.
Cukras, Catherine A., et al.. (2005). A Potential Interaction Between the RP1 and IMPDH1 Proteins. Investigative Ophthalmology & Visual Science. 46(13). 1710–1710.2 indexed citations
18.
Inglehearn, Chris F., et al.. (2005). Haploinsufficiency of Prpf8 Does Not Cause Retinal Degeneration. Investigative Ophthalmology & Visual Science. 46(13). 5263–5263.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.